baber/WOPTO huggingface dataset:
Patent NZ-281212-A (NZ)
Title: Ultrasonic contrast medium: microparticles containing a substance that is gaseous at body temperature
Inventor: HELDMANN DIETER
IPC: A61K49/22
Filed: 1995-02-10
Abstract: Novel gas-contg. microparticles (MP's) for prodn. of ultrasonic diagnostic prepns., consist of a mixt. of at least one surfactant (I), at least one non-surface active solid (II) and at least one component (III) which is in gaseous form at body temp. The novelty is that (III) is a substance (or mixt.) which is less soluble than air in water. Also claimed are: (a) an ultrasonic contrast agent (USCA), comprising MP in a physiologically compatible liq. suspension medium (SM), opt. contg. conventional additives; and (b) a kit for preparing the USCA, consisting of: a 1st container (C1) of vol. 5-10 ml, filled with SM and having a closure allowing removal of the contents under sterile conditions; and a 2nd container (C2), having a closure allowing addn. of SM under sterile conditions, filled with MP's and gaseous (III), the vol. of (C2) being sufficient to contain all of the SM in (C1). Pref. (I) is a phospholipid, sterol, glycolipid, ethoxylated soya sterol, polyoxyethylene (POE) fatty acid ester, ethoxylated castor oil (or hydrogenated deriv.). POE-polyoxypropylene polymer sucrose ester, POE fatty alcohol ether, (un)satd. 8-30C fatty acid, 14-30C fatty alcohol, mono, di- or triglyceride, fatty acid ester, xyloglyceride and/or POE sorbitan fatty acid ester.
Patent NZ-290080-A (NZ)
Title: Dihydrobenzo(thio)furan derivatives and pharmaceutical compositions
Inventor: SCHERZ MICHAEL WIARD
IPC: C07D333/54
Filed: 1995-07-19
Abstract: A compound having structure (1) wherein (a) X is oxygen or sulfur; (b) each Y is independently hydrogen or unsubstituted straight, branched or cyclic alkanyl having from 1 to about 3 carbon atoms, or the two Y's are bonded to form an alkanyl ring having from 3 to about 7 carbon atoms; (c) Z is hydrogen or unsubstituted branched or cyclic alkyl, or unsubstituted or alkanyl-substituted phenyl, having from 3 to about 10 atoms other than hydrogen; (d) W is straight, branched or cyclic alkyl or aryl, unsubstituted or substituted, saturated or mono- or di-unsaturated with double bonds except that no terminal carbon atom of W is part of a double bond; W having from 1 to about 15 atoms other than hydrogen; pharmaceutical compositions comprising such compounds, and methods of treating inflammation or pain using such compounds.
Patent NZ-322202-A (NZ)
Title: Aminocycloalkylpyrrolidine derivatives and salts thereof with antibacterial activity
Inventor: TAKEMURA MAKOTO
IPC: A23K20/195
Filed: 1996-11-22
Abstract: Antibacterial drugs comprising quinolone derivatives of formula (I), salts or hydrates thereof, wherein Q is formula (II) or (IV).
Patent NZ-331014-A (NZ)
Title: Anticoagulant agents useful in treatment of thrombosis
Inventor: BLACKBURN MICHAEL NEAL
IPC: C12N5/06
Filed: 1997-01-17
Abstract: n anti-factor IX monoclonal antibody having self-limiting neutralizing activity against Factor IX and the identifying characteristics of SB 249413, SB 249415, SB 249417, SB 257731 or SB 257732 is claimed. Also claimed are an immunoglobulin heavy chain complementary determining region having an amino acid sequence selected from SEQ. ID NO 8, 9 and 10 as defined in the specification and the nucleic acid molecule encoding it. Also claimed are an immunoglobulin light chain complementary determining region having an amino acid sequence selected from SEQ. ID NO 12, 13 and 14 as defined in the specification and the nucleic acid molecule encoding it.   Divisional filed as 501215
Patent NZ-332750-A (NZ)
Title: Process for resolving optical isomers of 2,3-dihydro-benzofuranol derivatives
Inventor: MARCINIAK GILBERT
IPC: C07D307/80
Filed: 1998-11-11
Abstract: his process of resolving the optical active isomers of the compound of formula (1) , where R"2, R"4, R"6, R"7 are methyl and Pg is hydrogen or a protecting group: comprises reacting the compound with lipase/candida cylindracae and vinyl acetate; separating the isomers and optionally deprotecting the 5-hydroxy group.
Patent NZ-500376-A (NZ)
Title: Intra-vaginal device for pigs
Inventor: RATHBONE MICHAEL JOHN
IPC: A61M31/00
Filed: 1997-05-28
Abstract: An intra-vaginal device having an elongate body (10) which is not articulated to be inserted in a pig with part on either side of the hymenal ring of a pig and a variable geometry retention means (8) dependent from that part of the elongate body to be located in the vestibule of the vaginal tract. The variable geometry retention means is capable of assuming a vestibular engagement from after release from the insertion mode.
Patent NZ-504270-A (NZ)
Title: Procedure for modifying the calling command to include location and authentication information
Inventor: HOKKANEN TUOMO
IPC: H04M15/16
Filed: 1998-11-04
Abstract: Procedure for processing the impulse of terminal equipment (3) in a telecommunications network (6) prior to execution of the function purported by the impulse, such as connection setup. According to the invention, the terminal equipment is connected to a processing module (2) and the impulse is processed in the processing module. The processing module adds information to the impulse such as authentication and location codes.
Patent NZ-507031-A (NZ)
Title: Apparatus for the production of pocketed coil springs
Inventor: WHITWORTH IAN JAMES
IPC: A47C23/04
Filed: 1999-03-29
Abstract: There  is  described apparatus for the  production  of pocketed  coil  springs. The apparatus comprises  a  coiling section in which a coil is formed from wire (1) fed  to  the coiling  section,  said coiling section  comprising  coiling elements  (2,  3,  4,  5) whose position and/or  orientation determines  the  form  of said coil,  and  an  encapsulation section  in  which  the coil is inserted between  juxtaposed sheets  of material and in which the sheets of material  are joined  together to form a pocket enclosing  the  coil.  The apparatus  further comprises programmable control means  (8) operably  linked to said coiling elements (2, 3,  4,  5)  in such a way as to control the position and/or orientation  of the coiling elements (2, 3, 4, 5).
Patent NZ-507976-A (NZ)
Title: DNA immunization to generate protective antibodies to a fragment of a major outer membrane protein (MOMP) of a strain of Chlamydia that encompasses epitopic sequences
Inventor: BURNHAM ROBERT C
IPC: C07K16/40
Filed: 1999-04-07
Abstract: A vector in an immunogenic composition comprising a nucleic acid such as DNA for immunization to generate a protective immune response in a mammalian host, including humans, to a major outer membrane protein (MOMP) of a strain of Chlamydia is described.  Preferably the immunogenic composition contains a nucleotide sequence encoding a fragment that generates antibodies that specifically react with the MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP fragment in the host.  The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.
Patent NZ-511099-A (NZ)
Title: Clamping device with spring biasing of jaws to attach pole to horizontal member such as bed frame and telescoping struts
Inventor: KEEPA ERIC GORDON HAUATA
IPC: F16B2/02
Filed: 2001-04-12
Abstract: Carrier 2 has one or more extendable struts 4,5 within base tube housing 3. Fixture 6 at the upper end of carrier 2 is provided for fastening an infusion carrier (not shown). Fixed jaw 10 is attached to housing 3. Sliding jaw 11 is movable relative to housing 3 and is biased by spring 13.
Patent NZ-511178-A (NZ)
Title: Directed public address system
Inventor: FRECSKA SANDOR A
IPC: H04R27/00
Filed: 2001-04-18
Abstract: Selectively activated speakers 12 are distributed throughout a predefined area and are connected to a central processing unit 32 via the central power unit 20.  Multiple radio frequency antennae 40 broadcast and receive RF signals coded with unique codes to the radio frequency identification badges worn by individuals located in the area.  By means of the response of a badge to the coded signal the processor determines the location of the individual within the area so as to be able to selectively broadcast and audio message to the speaker located closest to the intended recipient.
Patent NZ-515390-A (NZ)
Title: Robust autofocus system for a microscope
Inventor: GEUSEBROEK JAN-MARK
IPC: G02B7/36
Filed: 2000-05-30
Abstract: A method and apparatus for autofocusing of an optical instrument, especially a microscope (10) is disclosed. The autofocus scheme includes a digital gradient filter for generating a focus score from each captured image. Images may be captured at various positions and the focus scores analysed to determine a focus score maximum. The position corresponding to this maximum is then taken as the focus position. The spatial extent of the filter is preferably settable so that the digital filter settably selects elements of the image depending on their size in the image. Thus, the filtering process is controllable so that it is influenced by elements of the image whose size may be specified by the operator indirectly by way of the spatial extent of the filter. This allows the exclusion of small or large elements of the image from the autofocusing procedure, which the filter should preferably ignore. The autofocus scheme is particularly useful for autofocusing biological specimens.
Patent NZ-517367-A (NZ)
Title: Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flashes
Inventor: DOODS HENRI
IPC: A61K31/505
Filed: 2000-08-05
Abstract: The use of a clacitonin gene-related peptide (CGRP) antagonist for the preparation of a pharmaceutical composition for treating menopausal hot flushes.
Patent NZ-518658-A (NZ)
Title: Method of water treatment
Inventor: EVANS LIONEL
IPC: A61L2/00
Filed: 2002-04-30
Abstract: A method of inhibiting growth of microorganisms by establishing a vortex turbulated flow of water containing said microorganisms through a vertically orientated ultraviolet light transparent tube which is open at both ends generating an ultraviolet flow of radiation into the tube and through the vortex whereby the microorganisms are exposed to the ultraviolet radiation while passing down the tube. Recovering the water after it has exited the tube is also included.
Patent NZ-524989-A (NZ)
Title: Pumping arrangement for paint circulation and reduced pressure surges
Inventor: WOOD NIGEL CHARLES
IPC: F04B15/02
Filed: 2002-07-24
Abstract: A pumping arrangement for a paint circulation system comprising a reciprocating pump (13), and characterized by an alternating current induction motor (15), a rotary-to-linear motion converter (16) coupling the output of the induction motor (15) to a drive input of the pump (13), an alternating current frequency inverter (24a) controlling said induction motor, switch means (26) for reversing rotation of the induction motor (15) at the ends of the stroke of the reciprocating pump (13), and, a surge eliminator (28) communicating with the output side of said pump (13) to augment the pressure in the circulation system during stroke reversal of the pump.
Patent NZ-526078-A (NZ)
Title: Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them in the improvement of milk and milk-derived products
Inventor: GLENN MATTHEW
IPC: A61P9/12
Filed: 2001-11-28
Abstract: Disclosed are polynucleotides isolated from Lactobacillus rhamnosus, as well as probes and primers, genetic constructs comprising the polynucleotides, biological materials, including plants, microorganisms and multicellular organisms incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for using the polynucleotides and polypeptides are disclosed. In particular, these polypeptides are adherence and virulence protein A (Pav A) and Fibronectin binding protein AB2 Adherence and virulence protein A (Pav A) is a virulence factor that is widely distributed in bacteria and participates in adherence to host cells and soft tissue pathology. Fibronectin binding protein AB2 useful for altering the flavor and aroma in dairy products and to develop products that enhance adhesion to intestinal surface and cell lines, to enhance survival in intestinal environments, to alter metabolic and adhesion characteristics, enhance probiotics effects, interact win the human immune system and block or modify adherence of bacteria to mucosal surfaces, and can be incorporated as a carrier molecule in vaccines.
Patent NZ-526351-A (NZ)
Title: Dismountable hinge
Inventor: HALSALL KEVIN THOMAS
IPC: B65D6/22
Filed: 2003-06-09
Abstract: A hinge for a roto-molded lidded bin includes a first part 6 of substantially circular cross-section and having a concave surface 5 parallel to the rotational axis, and a second part being a linear groove 8 with a cross-section the major segment of a circle. The opening in the groove is of sufficient size so that the part 6 can be slipped into the groove using a translation motion that is transverse to the respective axes of the first and second parts and while the first and second parts are at a first predetermined rotational position with respect to each other. Thereafter the first and second parts remain interlocked irrespective of being in any other rotational position relationship. The hinge is particularly suitable for connection of a lid on a refuse bin, both the lid and the bin including the respective hinge parts being roto- molded.
Patent NZ-526558-A (NZ)
Title: Lentiviral vector-mediated gene transfer for inhibiting intraocular cellular proliferation
Inventor: STOUT J TIMOTHY
IPC: A61K35/74
Filed: 2001-12-18
Abstract: A lentiviral vector comprising a therapeutic gene that inhibits intraocular cellular proliferation or intraocular neovascularization is used in the manufacture of a medicament for inhibiting intraocular cellular proliferation or intraocular neovascularization an individual having an ocular disease. Preferably the ocular disease is selected from age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, glaucoma and proliferative vitreoretinopathy and the gene is selected from constitutively active form of the retinoblastoma gene, p16 gene, p21 gene, tissue inhibitor of metalloproteinase(TIMP)-1, TIMP-2, TIMP-3, TIMP-4, endostatin, angiostatin, endostatin XVIII, endostatin XV, the C-terminal hemopexin domain of matrix metalloproteinase-2, the kringle 5 domain of human plasminogen, a fusion protein of endostatin and angiostatin, a fusion protein of endostatin and the kringle 5 domain of human plasminogen, the monokine-induced by interferon-gamma (Mig), the interferon-alpha inducible protein 10 (IP10), a fusion protein of Mig and IP10, soluble FLT-1 (fms-like tyrosine kinase 1 receptor), and kinase insert domain receptor (KDR).
Patent NZ-528639-A (NZ)
Title: Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
Inventor: GERLACH MATTHIAS
IPC: A61K31/4985
Filed: 2002-03-13
Abstract: Disclosed herein are substituted pyrazolopyrimidines having general structures (I A) and (I B) (wherein the substituents for the variables shown in these structures are as defined in the specification), a method for their production, substance libraries containing these compounds, pharmaceutical compositions containing these compounds, medicaments containing these compounds, the use of these compounds in the production of medicaments for treating pain, epilepsy, schizophrenia, neurodegenerative diseases, in particular Alzheimer's disease, Huntington's disease and Parkinson's disease, for treating cerebral ischaemia and infarcts, psychosis caused by increased amino acid levels, cerebral oedema, conditions caused by an under-supply of the central nervous system, in particular in hypoxia, especially newborn hypoxia and anoxia, for treating AIDS-related dementia, encephalomyelitis, Tourette's syndrome, perinatal asphyxia, tinnitus, neuropathic pain, diseases of the respiratory tract, cancer, cardiac arrythmia, immune disorders and diseases, inflammatory conditions and diseases, renal shutdown, dyssomnia, strokes, thromboses, urinary incontinence, diabetes, psoriasis, septicaemic shock, cerebral traumas, glaucoma and/or congestive heart failure.
Patent NZ-536747-A (NZ)
Title: Preparation of modafinil comprising reaction with chloroacetamide
Inventor: LARGEAU DENIS
IPC: C07C/
Filed: 2003-05-23
Abstract: Disclosed is a process of preparing modafinil, comprising: (1) reacting benzhydrol with a suitable acid and thiourea to form a S-benzhydrylthiouronium salt; (2) reacting the S-benzhydrylthiouronium salt with a suitable base to form benzhydrylthiol; (3) reacting the benzhydrylthiol with chloroacetamide to form 2-(benzhydrylthiyl acetamide; (4) oxidising 2-(benzhydrylthiyl) acetamide with a suitable oxidising agent to form modafinil. Particularly disclosed is step (3) of the above reaction series.
Patent NZ-539685-A (NZ)
Title: Method and apparatus for high speed activation of oxygen scavenging compositions
IPC: B65D85/50
Filed: 2005-04-28
Abstract: A triggering unit for activating a film having an oxygen scavenging composition, the unit comprising a) a first driven roll and a second driven roll for driving the film through the triggering unit; b) a UV light source having an intensity from about 15 to 35 mW/cm and c) a shuttle system having a plurality of guide rolls and a plurality of shuttle rolls, the guide rolls and the shuttle rolls defining a film path that is capable of being in close proximity to the LW light source, the shuttle rolls adapted for maintaining film tension and controlling the exposure of the film to UV light by altering the length of the film path that is in close proximity to the UV light source.
Patent NZ-548018-A (NZ)
Title: Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the transport of electrons of the respiratory chain in phytopathogenic fungal organisms
Inventor: GOUOT JEAN-MARIE
IPC: A01N43/40
Filed: 2005-02-10
Abstract: Disclosed is a fungicidal composition comprising (a) a pyridylethylbenzamide derivative of general formula (I), in which the substituents are as defined in the specification, and b) a compound capable of inhibiting the transport of electrons of the respiratory chain in phytopathogenic fungal organisms; wherein the compound is selected from the group consisting of: i) diflumetorin; ii) compounds capable of inhibiting succinate dehydrogenase in phytopathogenic fungal organisms selected from the group consisting of N-[2-(1 ,3dimethyl-butyl)-phenyl]-5-fluoro-1,3-dimethyl-lH-pyrazole-4-carboxamide, N-(3',4'-dichloro-5-fluorobiphenyl-2-yl)-3-(difluoro-methyl)-l-methyl-1H-pyrazole-4-carboxamide, N-[2-(1,3-dimethylbutyl)-thiophen-3-yl] 1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, benodanil, carboxin, fenfuram, flutolanil, furametpyr, mepronil, boscalid, oxycarboxin and thifluzamide; and iii) compounds capable of inhibiting mitochondrial ubiquinol:ferricytochrome-c oxidoreductase in phytopathogenic fungal organisms selected from the group consisting of cyazofamid, fenamidone and famoxadone; and iv) a strobilurin derivative selected from the group consisting azoxystrobin, dimoxystrobin, fluoxastrobin, kresoxim-methyl, metominostrobin, trifloxystrobin, pyraclostrobin, picoxystrobin and 2-{2-[6-(3-chloro-2-methylphenoxy)-5-fluoro-pyrimidin-4-yloxy]-phenyl} 2-methoxyimino-N-methylacetamide; in a (a) / (b) weight ratio of from 0.01 to 20. Reference has been directed, in pursuance of section 16(1) of the Patents Act 1953, to patent No. 537608.
Patent NZ-548179-A (NZ)
Title: Azepinoindole derivatives with affinity for the farnesoid X receptor
Inventor: BUSCH BRETT
IPC: C07D471/04
Filed: 2004-12-01
Abstract: Disclosed are compounds of formula (I), wherein the substituents are as defined in the specification. The compounds modulate the activity of the farnesoid X receptor, and are useful in treating, preventing, or ameliorating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, atherosclerosis, atherosclerotic disease, atherosclerotic disease events, atherosclerotic cardiovascular disease, Syndrome X, diabetes mellitus, type II diabetes, insulin insensitivity, hyperglycemia, cholestasis and obesity.
Patent NZ-550125-A (NZ)
Title: Closure with integral gas barrier
Inventor: MCGEOUGH PETER MICHAEL
IPC: B65D41/32
Filed: 2005-03-24
Abstract: A method for producing a cap from an existing plastics component comprising a top panel 4 surrounded by a skirt, a plastics coated aluminium gas barrier foil 30, and a component 56 that carries a valve 52 adapted to fit inside and seal against an inner wall of a neck of a container to which the cap is fitted, the method comprising the steps of placing the barrier foil 30 adjacent the top panel and induction heat welding the foil 30 to the panel by melting the component indirectly by contact with the heated foil 30, such that a peripheral aluminium edge of the foil 30 cannot come into contact with the contents of a container closed by the cap in use.
Patent NZ-575572-A (NZ)
Title: Thiazole pyrazolopyrimidines as crf1 receptor antagonists
Inventor: CHEN ZHAOGEN
IPC: A61P25/24
Filed: 2007-09-17
Abstract: Disclosed is a thiazole pyrazolopyrimidine of formula (I) where the variables are as disclosed in the description. Examples of compounds of formula (I) include [2-( { 5-[7 -(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a ]pyrimidin-3-yI]-4-trifluoromethyl-thiazol-2-yl } -propyl-amino )-ethyI]-carbamic acid tert-butyl ester; (S)-1- { 5-[7 -(1-Ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-3-yI]-4-trifluoromethyl-thiazol-2-yl} -pyrrolidin-3-ylamine, hydrochloride and 3-[2-(2,5-Dimethyl-pyrrol-1-yl)-4-trifluoromethyl-thiazol-5-yI]-7 -(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament to treat anxiety, depression or substance abuse.
Patent NZ-580671-A (NZ)
Title: Pyrimidine derivatives
Inventor: SU WEI-GUO
IPC: C07D239/42
Filed: 2008-04-15
Abstract: Disclosed is a compound of formula (I) where the substituents are as disclosed in the description. Examples of compound of formula (I) are: N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine, N2-(3-ethynylphenyl)-N4-(2-methyl-1H-indol-5-yl)pyrimidine-2,4-diamine and N2-(3-bromophenyl)-N4-(2-methyl-1H-indol-5-yl)pyrimidine-2,4-diamine. Also disclosed is the use of a compound of formula (I) in the manufacture of a medicament for treating an angiogenesis-related disorder.
Patent NZ-582524-A (NZ)
Title: Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 comprising compounds with carboxamide and diazaspiro[4.5]dec-7-yl moities
Inventor: YAO WENQING
IPC: C07D471/10
Filed: 2008-06-20
Abstract: Disclosed are four compounds: 5-{ 3-Fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} -N,N-dimethylpyridine-2-carboxamide; 5-{ 3-Fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} -N-methylpyridine-2-carboxamide; N-Ethyl-5-{ 3-fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} pyridine-2-carboxamide; 5-{ 3-Chloro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} -N-ethylpyridine-2-carboxamide; and pharmaceutically acceptable salts thereof. The compounds are useful for: inhibiting activity of 11bHSD, the conversion of cortisone to cortisol in a cell, inhibiting the production of cortisol in a cell, and for treating obesity, diabetes, glucose intolerance, insulin resistance, hyperglycaemia (hyperglycemia), hypertension, hyperlipidaemia (hyperlipidemia), cognitive impairment, depression, dementia, glaucoma, cardiovascular disorders, osteoporosis, inflammation, metabolic syndrome, androgen excess; or polycystic ovary syndrome (PCOS).